Emerging therapies for sleep disorders.
There has been an upsurge in interest in treatments for sleep disorders recently, as new discoveries in the physiology of sleep-related brain neurotransmitter systems have been made. New targets for therapies have been identified in the field of insomnia, and these will be described in this article.
Wilson
Sue
S
Psychopharmacology Unit, University of Bristol, Bristol BS1 3NY.
D000081:Acetamides / Q000627:therapeutic use; D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D018755:GABA Agonists / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
D000081:Acetamides; D000929:Antidepressive Agents, Tricyclic; D018755:GABA Agonists; D006993:Hypnotics and Sedatives; D007192:Indenes; D007546:Isoquinolines; D018377:Neurotransmitter Agents; D012702:Serotonin Antagonists; C495910:ramelteon; C519150:almorexant